MEPOLIZUMAB and OFF LABEL USE

Overview

OFF LABEL USE is the #11 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 2,930 FDA adverse event reports linking MEPOLIZUMAB to OFF LABEL USE. This represents approximately 1.7% of all 173,706 adverse event reports for this drug.

Patients taking MEPOLIZUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OFF LABEL USE2,930 of 173,706 reports

OFF LABEL USE is a less commonly reported adverse event for MEPOLIZUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of MEPOLIZUMAB

In addition to off label use, the following adverse reactions have been reported for MEPOLIZUMAB:

ASTHMA — 12,416 reports
DYSPNOEA — 10,201 reports
WHEEZING — 6,904 reports
PRODUCT DOSE OMISSION ISSUE — 6,194 reports
COUGH — 4,939 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE — 4,917 reports
PNEUMONIA — 4,419 reports
DRUG INEFFECTIVE — 4,405 reports
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES — 4,148 reports
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION — 3,042 reports

Other Drugs Associated with OFF LABEL USE

The following drugs have also been linked to off label use in FDA adverse event reports:

0XYGEN ABACAVIR SULFATE ABATACEPT ABIRATERONE ACETATE ACALABRUTINIB ACETAMINOPHEN ACETAMINOPHEN 500MG ACETAMINOPHEN AND CODEINE ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN AND IBUPROFEN ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, ASPIRIN, AND CAFFEINE ACETAMINOPHEN, ASPIRIN, CAFFEINE ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE ACETAMINOPHEN, CAFFEINE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, IBUPROFEN

Does MEPOLIZUMAB cause OFF LABEL USE?

OFF LABEL USE has been reported as an adverse event in 2,930 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OFF LABEL USE with MEPOLIZUMAB?

OFF LABEL USE accounts for approximately 1.7% of all adverse event reports for MEPOLIZUMAB, making it a notable side effect.

What should I do if I experience OFF LABEL USE while taking MEPOLIZUMAB?

If you experience off label use while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.